A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO)

Registry ID

ZB012-03-001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ZENAS BIOPHARMA (USA) LLC

Start date

2024-11-20

Last update

2023-03-09

Conditions

• IGG4 RELATED DISEASE

Related clinical trials

• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY OF INEBILIZUMAB EFFICACY AND SAFETY IN IGG4 RELATED DISEASE

View on source registry